Literature DB >> 11958434

CD69 expression on lymphocytes and interleukin-15 levels in synovial fluids from different inflammatory arthropathies.

Ana M Ortiz1, Armando Laffon, Isidoro Gonzalez-Alvaro.   

Abstract

OBJECTIVE: The aim was to study a possible relationship between CD69 expression on lymphocytes and interleukin-15 (IL-15) levels in synovial fluid (SF) from patients with different inflammatory arthropathies.
METHODS: CD69 expression was assessed by two-color flow cytometry on different subsets of synovial fluid lymphocytes (SFL) obtained from patients with diagnoses of rheumatoid arthritis (RA), seronegative spondyloarthropathy (SSd), and crystal-associated arthritis (CAA). The IL-15 levels in synovial fluid supernatants were measured by enzyme-linked immunoassay (ELISA).
RESULTS: No significant differences between the three groups of arthropathies were observed in the distribution of synovial fluid lymphocyte subsets. CD69-positive SFL were mainly CD3-, CD45RO-, and CCR5-positive cells. Although no significant differences in the percentage of CD69-positive lymphocytes were observed between the three groups of patients, the highest level of CD69 expression on lymphocytes was observed in RA patients (mean fluorescence intensity 37.9 +/- 5.2 compared to 17.5 +/- 3.3 in SSd and 12.4 +/- 2.6 in CAA, P = 0.007 and P < 0.001, respectively). In addition, the expression of CD69 on SFL from RA correlated with their respective IL-15 levels measured in SF supernatants.
CONCLUSION: Our data provide in vivo evidence of the putative role that IL-15 can play in the high expression of CD69 on SFL from RA patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11958434     DOI: 10.1007/s00296-001-0161-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  13 in total

1.  A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis.

Authors:  A Julià; A Fernandez-Nebro; F Blanco; A Ortiz; J D Cañete; J Maymó; M Alperi-López; B Fernández-Gutierrez; A Olivè; H Corominas; A Erra; I Acosta-Colman; A Alonso; M López-Lasanta; R Tortosa; J Tornero; S Marsal
Journal:  Pharmacogenomics J       Date:  2015-04-21       Impact factor: 3.550

Review 2.  Mechanisms of bone resorption and new bone formation in spondyloarthropathies.

Authors:  Willis Huang; Edward M Schwarz
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

3.  The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study.

Authors:  Balázs Szalay; Barna Vásárhelyi; Aron Cseh; Tivadar Tulassay; Magdolna Deák; László Kovács; Attila Balog
Journal:  Clin Rheumatol       Date:  2013-08-11       Impact factor: 2.980

4.  Curcumin inhibits CD4(+) T cell activation, but augments CD69 expression and TGF-β1-mediated generation of regulatory T cells at late phase.

Authors:  Girak Kim; Mi Seon Jang; Young Min Son; Min Ji Seo; Sang Yun Ji; Seung Hyun Han; In Duk Jung; Yeong-Min Park; Hyun Jung Jung; Cheol-Heui Yun
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

5.  Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features.

Authors:  Raquel Celis; Núria Planell; José L Fernández-Sueiro; Raimon Sanmartí; Julio Ramírez; Isidoro González-Álvaro; José L Pablos; Juan D Cañete
Journal:  Arthritis Res Ther       Date:  2012-04-27       Impact factor: 5.156

6.  Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis.

Authors:  Isidoro González-Álvaro; Ana M Ortiz; José María Alvaro-Gracia; Santos Castañeda; Belen Díaz-Sánchez; Inmaculada Carvajal; J Alberto García-Vadillo; Alicia Humbría; J Pedro López-Bote; Esther Patiño; Eva G Tomero; Esther F Vicente; Pedro Sabando; Rosario García-Vicuña
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

7.  Interleukin-15 and interferon-gamma participate in the cross-talk between natural killer and monocytic cells required for tumour necrosis factor production.

Authors:  Isidoro González-Alvaro; Carmen Domínguez-Jiménez; Ana M Ortiz; Vanessa Núñez-González; Pedro Roda-Navarro; Elena Fernández-Ruiz; David Sancho; Francisco Sánchez-Madrid
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

8.  Differential expression of pro-inflammatory cytokines IL-15Ralpha, IL-15, IL-6 and TNFalpha in synovial fluid from rheumatoid arthritis patients.

Authors:  Alicia Santos Savio; Ana Cecilia Machado Diaz; Araceli Chico Capote; Jamilet Miranda Navarro; Yunier Rodríguez Alvarez; Ricardo Bringas Pérez; Miguel Estévez del Toro; Gerardo E Guillen Nieto
Journal:  BMC Musculoskelet Disord       Date:  2015-03-12       Impact factor: 2.362

9.  Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway.

Authors:  I González-Alvaro; A M Ortiz; C Domínguez-Jiménez; A Aragón-Bodi; B Díaz Sánchez; F Sánchez-Madrid
Journal:  Ann Rheum Dis       Date:  2008-10-28       Impact factor: 19.103

10.  CD69 does not affect the extent of T cell priming.

Authors:  Elisenda Alari-Pahissa; Laura Notario; Elena Lorente; Javier Vega-Ramos; Ana Justel; Daniel López; José A Villadangos; Pilar Lauzurica
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.